BMS-345541 (hydrochloride)

547757-23-3

291.78

DMSO : 20 mg/mL (68.54 mM; Need ultrasonic)

NF-kappaB

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC₅₀=0.3 uM, IKK-1 IC₅₀=4 uM). BMS-345541 binds at an allosteric site of IKK. IC50 & Target: IC50: 0.3 uM (IKK2), 4 uM (IKK1) In Vitro: BMS-345541 inhibits IKK-2 and IKK-1 in dose-dependent manner. BMS-345541 fails to inhibit a panel of both serine/threonine and tyrosine kinases at concentrations as high as 100 uM. MS-345541 at concentrations as high as 100 uM fails to block both the anisomycin-stimulated phosphorylation of c-Jun and LPS-stimulated activation of MAPKAP K2 in THP-1 cells, as well as the EGF-stimulated phosphorylation of STAT3 in H292 cells^[1]. BMS-345541 treatment results in a concentration-dependent inhibition of melanoma cell proliferation in SK-MEL-5, A375, and Hs 294T cells. BMS-345541 (0, 100 uM) shows apoptotic features as revealed by TUNEL staining and nuclear condensation^[2]. In Vivo: BMS-345541 (10 mg/kg, p.o.) results in prolonged serum drug levels, with concentrations sustained at or above 1 uM for many hours in mice. BMS-345541 dose-dependently inhibits the production of TNFalpha measured in the serum of animals challenged with an intraperitoneal administration of LPS^[1]. BMS-345541 (0, 10, 25, and 75 mg/kg, p.o.) effectively inhibits SK-MEL-5 tumor growth in a dose-dependent manner in the mice. Tumor-bearing mice treated with 75 mg/kg of BMS-345541 show effective inhibition of growth of SK-MEL-5, A375, and Hs 294T tumors by 86+/-2.8%, 69+/-11% and 67+/-3.4%, respectively^[2]. BMS-345541 (30 and 100 mg/kg, p.o.) is effective in blocking both clinical and histological endpoints of inflammation and injury in mice^[3].